Cell and agonist‐specific regulation of genes for matrix metalloproteinases and their tissue inhibitors by primary glial cells

An imbalance in the matrix metalloproteinase (MMP) : tissue inhibitor of MMP (TIMP) ratio may be associated with tissue injury. Here, we studied the regulation of TIMP and MMP gene expression in primary glial cultures to ascertain the factors involved in the regulation of these genes in conditions of inflammatory neuropathology. Astrocytes were found to basally express TIMP‐1 and TIMP‐3 mRNA while microglia expressed only TIMP‐2 mRNA. TIMP‐4 mRNA was not detectable in either cell type. Treatment with interferon‐α (IFN‐α), IFN‐γ, interleukin‐3 (IL‐3), IL‐6 or tumor necrosis factor‐α (TNF‐α) did not alter expression of the TIMP genes. However, in astrocytes, but not in microglia, serum, IL‐1β or lipopolysaccharide (LPS) evoked a dose‐ and time‐dependent increase in TIMP‐1 mRNA and a coincident down‐regulation of the TIMP‐3 gene. Astrocytes were found to express mRNA constitutively for MMPs ‐3, ‐11 and ‐14. In contrast, microglia expressed only MMP‐12 mRNA under basal conditions. IL‐1β enhanced MMP‐3 mRNA levels while LPS increased the MMP‐3, ‐9, ‐12, ‐13 and ‐14 mRNAs. Our findings reveal that regulatory control of TIMP and MMP gene expression by glial cells is agonist‐ and cell‐type specific, and suggest that innate immune signals govern the temporal and spatial expression patterns of TIMP and MMP genes in neuroinflammatory conditions of the CNS.

[1]  F. Barkhof,et al.  Blood–brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis , 2005, Neurobiology of Disease.

[2]  J. Antel,et al.  TLR Signaling Tailors Innate Immune Responses in Human Microglia and Astrocytes1 , 2005, The Journal of Immunology.

[3]  I. Campbell,et al.  TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES, INFLAMMATION, AND THE CENTRAL NERVOUS SYSTEM , 2005 .

[4]  G. Rosenberg,et al.  Multiple roles for MMPs and TIMPs in cerebral ischemia , 2005, Glia.

[5]  T. Joh,et al.  Matrix Metalloproteinase-3: A Novel Signaling Proteinase from Apoptotic Neuronal Cells That Activates Microglia , 2005, The Journal of Neuroscience.

[6]  H. Aldskogius.  Repairing CNS myelin—astrocytes have to do their jobs , 2005, Experimental Neurology.

[7]  J. Madri,et al.  MMP‐2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP‐9 expression and activity , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  R. Banati,et al.  Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease , 2004, Brain Research Reviews.

[9]  A. Hinkkanen,et al.  Treatment of Experimental Autoimmune Encephalomyelitis with a Neurotropic Alphavirus Vector Expressing Tissue Inhibitor of Metalloproteinase‐2 , 2004, Scandinavian journal of immunology.

[10]  A. Achiron,et al.  Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus , 2004, Clinical and experimental immunology.

[11]  V. Trajković,et al.  Astrocyte‐induced regulatory T cells mitigate CNS autoimmunity , 2004, Glia.

[12]  D. Dormont,et al.  Differential regulation of gelatinase A and B and TIMP-1 and -2 by TNFalpha and HIV virions in astrocytes. , 2004, Microbes and infection.

[13]  I. Campbell,et al.  The TIMPs tango with MMPs and more in the central nervous system , 2004, Journal of neuroscience research.

[14]  G. Opdenakker,et al.  Matrix Metalloproteinase-9 Facilitates Remyelination in Part by Processing the Inhibitory NG2 Proteoglycan , 2003, The Journal of Neuroscience.

[15]  H. Gendelman,et al.  Regulation of tissue inhibitor of metalloproteinase‐1 by astrocytes: Links to HIV‐1 dementia , 2003, Glia.

[16]  N. Berman,et al.  The primary phase of infection by pathogenic simian-human immunodeficiency virus results in disruption of the blood-brain barrier. , 2003, AIDS research and human retroviruses.

[17]  S. Rojas,et al.  Astrocyte‐targeted expression of interleukin‐6 protects the central nervous system during neuroglial degeneration induced by 6‐aminonicotinamide , 2003, Journal of neuroscience research.

[18]  P. Saenger.  Dose Effects of Growth Hormone during Puberty , 2003, Hormone Research in Paediatrics.

[19]  S. Lorenzl,et al.  Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. , 2003, Stroke.

[20]  J. Eriksson,et al.  Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors , 2003, Oncogene.

[21]  S. Lorenzl,et al.  Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases , 2003, Journal of the Neurological Sciences.

[22]  J. Uney,et al.  Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons , 2003, Molecular and Cellular Neuroscience.

[23]  E. Waubant,et al.  IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS , 2003, Neurology.

[24]  J. Forrester,et al.  Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. , 2002, The American journal of pathology.

[25]  N. Rothwell,et al.  Expression of interleukin‐1 receptors and their role in interleukin‐1 actions in murine microglial cells , 2002, Journal of neurochemistry.

[26]  A. Minagar,et al.  The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis , 2002, Journal of the Neurological Sciences.

[27]  G. Rosenberg.  Matrix metalloproteinases in neuroinflammation , 2002, Glia.

[28]  L. Noble,et al.  Matrix Metalloproteinases Limit Functional Recovery after Spinal Cord Injury by Modulation of Early Vascular Events , 2002, The Journal of Neuroscience.

[29]  A. Hinkkanen,et al.  Up‐regulation of MMP‐8 and MMP‐9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis , 2002, Clinical and experimental immunology.

[30]  J. Fawcett,et al.  Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. , 2002, Brain research. Molecular brain research.

[31]  M. Moscarello,et al.  The Up-regulation of Stromelysin-1 (MMP-3) in a Spontaneously Demyelinating Transgenic Mouse Precedes Onset of Disease* , 2002, The Journal of Biological Chemistry.

[32]  A. Newby,et al.  Tissue Inhibitor of Metalloproteinase-3 Induces a Fas-associated Death Domain-dependent Type II Apoptotic Pathway* , 2002, The Journal of Biological Chemistry.

[33]  I. Campbell,et al.  Cytokines Regulate Microglial Adhesion to Laminin and Astrocyte Extracellular Matrix via Protein Kinase C-Dependent Activation of the α6β1 Integrin , 2002, The Journal of Neuroscience.

[34]  L. Kaczmarek,et al.  Gelatinase B and TIMP‐1 are regulated in a cell‐ and time‐dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia , 2002, The European journal of neuroscience.

[35]  I. Campbell.  Cytokine-mediated inflammation and other actions in the central nervous system. , 2002, Ernst Schering Research Foundation workshop.

[36]  A. Vaheri,et al.  Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. , 2001, The American journal of pathology.

[37]  R. Dantzer,et al.  Rat microglial cells secrete predominantly the precursor of interleukin‐1β in response to lipopolysaccharide , 2001, The European journal of neuroscience.

[38]  E. Waubant,et al.  IFN-β1a May Increase Serum Levels of TIMP-1 in Patients with Relapsing-Remitting Multiple Sclerosis , 2001 .

[39]  B. Blom,et al.  Down-regulation of the macrophage lineage through interaction with OX2 (CD200). , 2000, Science.

[40]  A. Stalder,et al.  Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. , 2000, The American journal of pathology.

[41]  A. Stalder,et al.  Astrocyte-Targeted Expression of IL-12 Induces Active Cellular Immune Responses in the Central Nervous System and Modulates Experimental Allergic Encephalomyelitis1 , 2000, The Journal of Immunology.

[42]  Burkhard Becher,et al.  Brain‐immune connection: Immuno‐regulatory properties of CNS‐resident cells , 2000, Glia.

[43]  R. Sciot,et al.  Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. , 1999, The Journal of clinical investigation.

[44]  P Bacchetti,et al.  Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. , 1999, Neurology.

[45]  P. Fuhr,et al.  Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy , 1999, Neurology.

[46]  T. Kordula,et al.  Reprogramming of TIMP‐1 and TIMP‐3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines , 1999, FEBS letters.

[47]  G. Burmester,et al.  Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. , 1999, The Journal of rheumatology.

[48]  Y. Sun,et al.  Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma. , 1998, Journal of immunology.

[49]  I. Campbell,et al.  Astrocyte-Targeted Expression of IFN-α1 Protects Mice from Acute Ocular Herpes Simplex Virus Type 1 Infection , 1998, The Journal of Immunology.

[50]  G. Rosenberg,et al.  Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[51]  A. Stalder,et al.  Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. , 1998, The American journal of pathology.

[52]  Voon Wee Yong,et al.  Matrix metalloproteinases and diseases of the CNS , 1998, Trends in Neurosciences.

[53]  A. Stalder,et al.  RNAse protection assays for the simultaneous and semiquantitative analysis of multiple murine matrix metalloproteinase (MMP) and MMP inhibitor mRNAs. , 1997, Journal of immunological methods.

[54]  J. Cossins,et al.  Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor , 1997, Journal of Neuroimmunology.

[55]  D. Rappolee,et al.  Basement Membrane and Repair of Injury to Peripheral Nerve: Defining a Potential Role for Macrophages, Matrix Metalloproteinases, and Tissue Inhibitor of Metalloproteinases-1 , 1996, The Journal of experimental medicine.

[56]  J. Sedgwick,et al.  Microglia induce CD4 T lymphocyte final effector function and death , 1996, The Journal of experimental medicine.

[57]  R. Sobel,et al.  Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions , 1996, Journal of neuropathology and experimental neurology.

[58]  N. Bersch,et al.  Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. , 1995, Blood.

[59]  P. Gottschall,et al.  Cytokines Regulate Gelatinase A and B (Matrix Metalloproteinase 2 and 9) Activity in Cultured Rat Astrocytes , 1995, Journal of neurochemistry.

[60]  L. Steinman,et al.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. , 1994, The Journal of clinical investigation.

[61]  R. Salonen,et al.  Semliki Forest virus infects mouse brain endothelial cells and causes blood-brain barrier damage , 1994, Journal of virology.

[62]  L. Mucke,et al.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[63]  K. Iwata,et al.  Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.

[64]  E. Brown,et al.  Molecular characterization and expression of the gene encoding human erythroid-potentiating activity , 1985, Nature.

[65]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .